In a repositioning screen using splicing reporters designed to follow the switch in FGFR2 splicing, we have found three novel compounds that regulate EMT and decrease tumor growth in prostate cancer mouse xenografts. This evidence concerns the gene FGFR2 and prostate carcinoma.